To determine if newer influenza vaccines can safely improve seroprotection rates of older
adults, we compared three licensed trivalent inactivated vaccines (TIVs) in a randomized …

BACKGROUND: Although influenza is a major public health concern among adults≥ 60
years of age, few large, prospective studies of influenza vaccines have been conducted in …

We conducted a randomized, controlled, multicenter, phase II study to evaluate the
immunogenicity and safety of an investigational intradermal (ID) trivalent influenza vaccine …

Cellular immunity is important for protection against the serious complications of influenza in
older adults. As it is unclear if newer influenza vaccines elicit greater cellular responses than …

Background A number of enhanced influenza vaccines have been developed for use in
older adults, including high-dose, MF59-adjuvanted, and intradermal vaccines. Methods We …

Background Enhanced influenza vaccines may improve protection for older adults, but
comparative immunogenicity data are limited. Our objective was to examine immune …

Background Influenza remains a significant problem in elderly despite widespread
vaccination coverage. This randomized, phase-I study in elderly compared different …

Background As compared with a standard-dose vaccine, a high-dose, trivalent, inactivated
influenza vaccine (IIV3-HD) improves antibody responses to influenza among adults 65 …

Background A randomized trial demonstrated that a high-dose inactivated influenza vaccine
(IIV-HD) was 24.2% more efficacious than a standard-dose vaccine (IIV-SD) against …

Adults over the age of 60‐65 years suffer disproportionally from seasonal influenza,
experiencing high rates of complications, exacerbation of underlying medical comorbidities …